Efficacy of CPAP Therapy on Pulmonary Function Test in Patients With COPD-OSA Overlap Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate efficacy of CPAP Therapy on Pulmonary Function Test in Patients With COPD-OSA Overlap Syndrome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CPAP Improves the Walking Capacity in Patients With COPD and OSA

NCT01915641

Walking Capacity

COMPLETED NA

Noninvasive Positive Pressure Ventilation in Overlap Syndrome

NCT03184714

COPD Sleep Apnea Syndromes Non-invasive Positive Pressure Ventilation

UNKNOWN NA

The Effects of Continuous Positive Airway Pressure on Overlap Syndrome

NCT00914264

COPD & OSA

COMPLETED

Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome

NCT01033266

Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease

COMPLETED

Prevalence of OSA in COPD and the Clinical Impact of OSA Diagnosis and Treatment

NCT05042154

Prevalence of OSA in Patients Hospitalized With COPD Exacerbation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate efficacy of CPAP Therapy on Pulmonary Function Test in Patients With COPD-OSA Overlap Syndrome by 6 minute walking distance and oxygen consumption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD OSA Lung Function Decreased

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

To compare pulmonary function of COPD-OSA overlap subjects who using and not using (waiting list for PAP therapy) in the period of 2 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPAP therapy

CPAP therapy will be used in this arm for 2 month.

Group Type EXPERIMENTAL

CPAP therapy

Intervention Type DEVICE

Continous positive airway pressure therapy

Control

CPAP therapy will not be used in this arm for 2 month. (subject were assign to normal waiting list in order to borrowing hospital PAP machine.)

Group Type OTHER

Control

Intervention Type OTHER

No CPAP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPAP therapy

Continous positive airway pressure therapy

Intervention Type DEVICE

Control

No CPAP

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis with COPD by GOLD guideline criteria (Post bronchodilator FEV1/FVC \< 0.7 or \< LLN) with post bronchodilator FEV1 = 30-80%
* Diagnosis with obstructive sleep apnea with AHI \> 15 event/hr. (Moderate OSA or more)
* Age between 40-80 years
* Stable disease prior to inclusion.

Exclusion Criteria

* Diagnosis with \> 50% of central sleep apnea event
* History of COPD exacerbation during the past 8 week prior to inclusion.
* Subjects who cannot perform spirometry test or walking test
* Subjects with recording history of chronic heart failure, significant arrhythmias, acute myocardial infarction, moderate to severe mitral or aortic valve disease and pulmonary hypertension.
* Subjects with interstitial lung disease.
* Subjects with neuromuscular disease.
* Subjects with morbid obesity (BMI \>/=35)
* Subjects with chronic respiratory infection.
* Subjects with chronic CO2 retension (PaCO2 \>/= 45 from arterial blood gas analysis) or Transcutaneous CO2 during sleep test \>/= 45 or Serum bicarbonate level \> 27
* Subjects with acute or active respiratory infecton during 2 week prior to inclusion.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No